cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Agenus Inc
51 own
88 watching
Current Price
$5.31
$0.34
(6.84%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
696.99M
52-Week High
52-Week High
42.60000
52-Week Low
52-Week Low
4.78000
Average Volume
Average Volume
1.46M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization696.99M
icon52-Week High42.60000
icon52-Week Low4.78000
iconAverage Volume1.46M
iconDividend Yield--
iconP/E Ratio--
What does the Agenus Inc do?
Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3. In addition, the company develops vaccine programs, such as Prophage cancer vaccine candidate; AutoSynVax, a synthetic cancer vaccine program targeting the neo-epitope landscape in cancer patients; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a novel class of tumor specific neo-epitopes. Further, Agenus Inc. develops QS-21 Stimulon, a saponin-based vaccine adjuvant that has completed Phase III clinical trials for the treatment of malaria and shingles. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Read More
News & Events about Agenus Inc.
Business Wire
9 months ago
Immuno-oncology leader, Agenus (Nasdaq: AGEN), shared promising data today from its Phase 1b trial on the botensilimab and balstilimab combination at a late-breaking session at the 2023 ESMO World...
Business Wire
11 months ago
Agenus (Nasdaq: AGEN), a leading immuno-oncology company dedicated to developing innovative treatments for cancer and infectious diseases, today announced a data update on botensilimab (multifunctional CTLA-4 antibody) in combination with balstilimab (PD-1 antibody) for patients with...
Zolmax
11 months ago
Shares of Agenus Inc. (NASDAQ:AGEN Get Rating) have earned an average rating of Moderate Buy from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average ...
Business Wire
12 months ago
Agenus (Nasdaq: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, today announced plans to present clinical data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, to be held June 2-6 in Chicago, IL. Data from a...
Zolmax
1 year ago
Agenus (NASDAQ:AGEN Get Rating)s stock had its buy rating reaffirmed by investment analysts at B. Riley in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $8.00 price target on the biotechnology companys ...
Frequently Asked Questions
Frequently Asked Questions
What is Agenus Inc share price today?
plus_minus_icon
Can Indians buy Agenus Inc shares?
plus_minus_icon
How can I buy Agenus Inc shares from India?
plus_minus_icon
Can Fractional shares of Agenus Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Agenus Inc stocks?
plus_minus_icon
What is today’s traded volume of Agenus Inc?
plus_minus_icon
What is today’s market capitalisation of Agenus Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Agenus Inc?
plus_minus_icon
What percentage is Agenus Inc down from its 52-Week High?
plus_minus_icon
What percentage is Agenus Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$5.31
$0.34
(6.84%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00